Rare Hemophilia Factors Market: Current Analysis and Forecast (2023-2030)

Rare bleeding disorders (RBDs) are autosomal recessive diseases including the inherited deficiencies of coagulation factors like fibrinogen, factor (F) II, III, FV, FVII, FX, FXI, FXIII, and others. These disorders are mainly caused by mutations or changes to the gene. The market is primarily driven by the increasing prevalence of rare blood disorders, such as hemophilia. These conditions are often inherited from affected parents and can result in symptoms such as uncontrolled bleeding episodes. As the global population ages, the incidence of rare blood disorders is expected to rise, thus fueling the demand for rare hemophilia factors therapeutics. Additionally, pharmaceutical advancements in the drugs have improved the safety and efficacy of rare hemophilia factors therapeutics, further driving market growth. Separate studies have found that aging patients encounter problems typical of old age compounded by hemophilia, which can cause bleeding in joints among other problems. Obesity is also a concern for people with hemophilia as they age something that can worsen joint bleeds and cause mobility issues.

The Rare Hemophilia Factors Market is expected to grow at a strong CAGR of 5.2% during the forecast period owing to the rising geriatric population. Rare bleeding disorders encompass a group of inherited blood clotting disorders that are less common than hemophilia. These disorders are often acquired by people of old age. According to the U.S. Census Bureau, the global population aged 65 and older is projected to reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide.

Based on type, the market is categorized into Factor I, Factor II, Factor VII, Factor X, Factor XIII, and others. The Factor VII segment held the majority share of the market in 2022 because of a high incidence of this deficiency. According to the National Bleeding Disorders Foundation, Factor VII deficiency has an incidence of 1 in 300,000-500,000 people or 2.5 cases per million. Factor VII is one of the most important coagulation proteases in the clotting cascade and is largely responsible for starting the proteolytic events that ultimately result in thrombin generation, fibrin deposition, and platelet activation. The deficiency is usually inherited in an autosomal recessive manner equally among men and women, both parents must carry the gene to carry it to their children. Hence, the Factor VII segment held a significant share of the market in the year 2022.

Based on treatment, the market is segmented into factor concentrates, fresh frozen plasma, cryoprecipitate, and others. The fresh frozen plasma segment is expected to grow with the highest CAGR during the forecast period owing to rising demand for medicines, the need for safe options for medicines, strategic collaborations and collaborations, and innovative product launches that have further increased the demand for intelligent products. When patients are revived with fresh frozen plasma rather than crystalloid or colloid, they are less likely to develop a dilutional coagulopathy. Fresh frozen plasma can be used as a treatment method for nearly all rare blood clotting factor deficiency types. Thus, the fresh frozen plasma segment is expected to gain prominence in the market in the forecast period.

For a better understanding of the market adoption of the rare hemophilia factors industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of rare hemophilia factors in 2022. Several factors such as the availability of cutting-edge and innovative products, growing awareness of health concerns, the rising geriatric population in the region are increasing the demand for therapeutics, and loaded investment in rare bleeding disorder drug discovery are driving the market in the region. For instance, in 2020, U.S.-based Regeneron Pharmaceuticals partnered with Intellia to co-develop potential treatments for rare blood disorders, which are genetic in fashion that prevent blood from clotting properly. North America dominated the rare hemophilia factors market among regions in the year 2022.

Some of the major players operating in the market include: Novo Nordisk A/S; Bayer AG; CSL; Takeda Pharmaceutical Company Limited; Bio Products Laboratory Ltd.; Octapharma AG; F. Hoffmann-La Roche Ltd; KM Biologics; GC Biopharma Corp.